HOOKIPA Pharma Inc.
https://www.hookipapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HOOKIPA Pharma Inc.
Finance Watch: Merrimack And LianBio Are Latest To Liquidate As Options Run Out
Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.
Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS
A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
- Other Names / Subsidiaries
-
- Hookipa Biotech AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice